Posts Tagged 'blood clots'

Bayer expects more lawsuits, according to report

Bayer has about 11,300 lawsuits pending from “persons alleged to have suffered personal injuries, some of them fatal” as a result of using the birth control pills Yasmin, Beyaz, and Yaz and their generic versions. And the company is expecting even more.

That’s from Bayer’s annual report, assessing the company’s status for 2011. The report provides a summation of the legal troubles the company has been dealing with over its oral contraceptives, which according to the lawsuits, cause an increased risk ...

continue reading...

Yaz maker Bayer bidding on pricey acquisition

According to Bloomberg, German corporation Bayer is bidding on Pfizer’s animal-health unit.

Bayer’s chief financial officer said last month that the company planned to cut its debt by $1.3 billion to give it more flexibility for a potential takeover.

According to the report, the Pfizer unit could fetch between $14 billion and $18 billion.

See the report here:

https://www.bloomberg.com/news/2012-03-07/bayer-is-said-to-consider-making-offer-for-pfizer-s-animal-health-division.html

Bayer is the manufacturer of Yaz, Yasmin, Beyaz, and Ocella — birth control pills that contain the compound drospirenone.

Those pills have served as the ...

continue reading...

Report says Yaz, Yasmin big money-makers for Bayer

Shannon Pettypiece of Bloomberg Television provides some context for the recent national debates about birth control, pointing out that birth control constitutes “big business for big pharma.”

In a recent report, Ms. Pettypiece observed that Americans spent $5 billion last year for birth control. She said the German corporation Bayer gets about $1.5 billion a year from its drugs Yaz and Yasmin.

See the video here:

https://www.bloomberg.com/video/87718882/

Several studies show that Yaz, Yasmin, continue reading...

Yaz/Beyaz maker Bayer considering “significant” aquisition

Bayer, the German corporation that manufactures birth control pills Yaz, Beyaz and Yasmin, could finance a “significant” acquisition using a combination of debt, equity and its portfolio assets, Bloomberg reports.

Bloomberg cites an interview with Bayer’s Chief Financial Officer Werner Baumann, who said the company would only sell one of its three units “on the merits of its own strategic assessment.”

“You will not find us in a situation where we say we want to buy this, therefore we have to sell ...

continue reading...

Formulation with controversial compound approved

The federal Food and Drug Administration has approved a new, lower-dose formulation of a Bayer corporation drug used to treat menopausal symptoms.

The drug Angeliq contains drospirenone, a synthetic progestogen that may elevate the levels of potassium in the body.

“We are pleased by the approval of this important new lower-dose option for menopausal women,” Bayer HealthCare Pharmaceuticals VP and head of U.S. medical affairs Pamela Cyrus said. “The availability of the new lower dose of Angeliq supports current guidelines which recommend ...

continue reading...

Journalist: Women should be aware of Yaz/Beyaz risks

A recent piece in the magazine “Ms.” by journalist Holly Grigg-Spall urges more women to educate themselves about potential health risks concerning the birth control pills Yaz and Beyaz, manufactured by German corporation Bayer.

Ms. Grigg-Spall points out that Yaz became the most popular birth control pill in the U.S. soon after its release in 2006, as the result of a marketing campaign that the federal Food and Drug Administration subsequently ruled to be misleading. The FDA requested that Bayer run ...

continue reading...
Page 30 of 31 «...10202728293031